[Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients].

Ann Dermatol Venereol

Service de dermatologie et allergologie, faculté de médecine, Sorbonne université, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, France. Electronic address:

Published: January 2019

Aim: Our aim was to assess the prevalence of adverse effects (AEs) pertaining to the use and withdrawal of hydroxychloroquine (HCQ) in dermatological outpatients.

Patients And Methods: We conducted a retrospective study between January 2013 and June 2014 that included consecutive patients currently or previously receiving HCQ seen in our department. AEs were collated using a standardized questionnaire and validated by clinical and laboratory examination. Drug causality was evaluated using the updated French drug reaction causality assessment method. The main evaluation criterion was the prevalence of AEs in which HCQ had an intrinsic imputability score of I>2.

Results: We included 102 patients (93 of whom were women, with a median age of 44.5; range: 22-90years). HCQ was given for cutaneous lupus in most cases (n=70). At least one AE was reported for 55 patients. Among the 91 reported AEs, 59 (65%) had an HCQ intrinsic imputability score I>2. AEs were responsible for permanent HCQ discontinuation in 19 cases. Of these, 8 were unrelated to HCQ based on imputability score. The most common AEs associated with HCQ were gastrointestinal and cutaneous signs. Of the 8 patients diagnosed with retinopathy, only 3 were confirmed after reevaluation.

Conclusion: AEs associated with HCQ were reported for over 50% of patients and were responsible for permanent HCQ discontinuation in one-third of cases. A more in-depth evaluation of imputability seems necessary, particularly regarding ophthalmological symptoms, since in two thirds of cases the reasons for discontinuation were not related to HCQ.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2018.03.168DOI Listing

Publication Analysis

Top Keywords

imputability score
12
hcq
11
hcq intrinsic
8
intrinsic imputability
8
responsible permanent
8
permanent hcq
8
hcq discontinuation
8
aes associated
8
associated hcq
8
aes
7

Similar Publications

Background: Recommended treatment after acute coronary syndrome (ACS) involves high-intensity statin therapy to achieve the low-density lipoprotein (LDL-C) target of<1.4mmol/L (European guidelines), but many patients discontinue statins because of real or perceived side-effects. Whether body mass index (BMI) influences statin intolerance remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Imipenem-cilastatin, a carbapenem antibiotic, can cause rare side effects such as seizures, as highlighted by a case involving a 20-year-old male who experienced seizures and respiratory distress after its administration.
  • Despite initial anti-epileptic treatment, seizures recurred until the antibiotic was discontinued, leading to the patient's stabilization, which suggests a link between the medication and the seizures.
  • This case emphasizes the need for healthcare providers to recognize and monitor the potential neurological effects of imipenem-cilastatin, especially in vulnerable patients, and to consider both the benefits and risks when choosing antibiotics.
View Article and Find Full Text PDF

Sulfamethoxazole-induced crystal nephropathy: characterization and prognosis in a case series.

Sci Rep

March 2024

Physiology Unit, Service des Explorations Fonctionnelles Multidisciplinaires, AP-HP, Hôpital Tenon, 4 Rue de la Chine, 75020, Paris, France.

Cotrimoxazole (Trimethoprim/Sulfamethoxazole-SMX) is frequently used in critically ill and immunocompromised patients. SMX is converted to N-acetyl-sulfamethoxazole (NASM) and excreted by the kidneys. NASM may form crystals in urine, especially in acid urine, that may induce a crystalline nephropathy.

View Article and Find Full Text PDF

Background: Current standards for toxicity reporting do not fully capture the impact of adverse events (AEs) on patients' quality of life (QoL). This study aimed to evaluate the association between toxicity and QoL by using toxicity scores that take into account CTCAE grade grouping and AE duration and cumulation.

Methods: Analyses were performed on the AURELIA trial dataset, including 361 patients with platinum-resistant ovarian cancer treated with chemotherapy alone or with bevacizumab.

View Article and Find Full Text PDF

Background: The development of direct-acting antivirals directed against the Hepatitis C Virus has dramatically modified the therapeutic approach to chronic hepatic viral disease. Larger use of such drugs has also led to increasing reports about their adverse effects. This report aimed to describe a case of leucocytoclasic vasculitis following treatment based on the sofosbuvir/ledipasvir regimen with complete disappearance shortly after withdrawal in a 61-year-old patient treated for genotype 1 hepatitis C.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!